{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33290323",
  "DateCompleted": {
    "Year": "2021",
    "Month": "09",
    "Day": "23"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1097/WNF.0000000000000424"
    ],
    "Journal": {
      "ISSN": "1537-162X",
      "JournalIssue": {
        "Volume": "44",
        "Issue": "1",
        "PubDate": {
          "MedlineDate": "2021 Jan-Feb 01"
        }
      },
      "Title": "Clinical neuropharmacology",
      "ISOAbbreviation": "Clin Neuropharmacol"
    },
    "ArticleTitle": "Fluoxetine-induced Systemic Hypertension in a 12-Year-Old Girl: A Case Report.",
    "Pagination": {
      "StartPage": "35",
      "EndPage": "36",
      "MedlinePgn": "35-36"
    },
    "Abstract": {
      "AbstractText": [
        "Fluoxetine, a selective serotonin reuptake inhibitor, is an efficacious medication in social anxiety disorder with a generally well-tolerated adverse effect profile. However, infrequent side effects may occur during treatment. Here, we report a case of systemic hypertension in a 12-year-old female patient with social anxiety disorder receiving fluoxetine treatment. To the best of our knowledge, this is the first report of fluoxetine-induced systemic hypertension in children and adolescences."
      ],
      "CopyrightInformation": "Copyright \u00a9 2020 Wolters Kluwer Health, Inc. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "From the Child and Adolescent Psychiatry Department, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey."
          }
        ],
        "LastName": "Tanir",
        "ForeName": "Ya\u015far",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "\u00d6zdemir",
        "ForeName": "Yahya Esad",
        "Initials": "YE"
      }
    ],
    "PublicationTypeList": [
      "Case Reports",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Clin Neuropharmacol",
    "NlmUniqueID": "7607910",
    "ISSNLinking": "0362-5664"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Serotonin Uptake Inhibitors"
    },
    {
      "RegistryNumber": "01K63SUP8D",
      "NameOfSubstance": "Fluoxetine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Child"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Fluoxetine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "chemically induced",
        "diagnosis"
      ],
      "DescriptorName": "Hypertension"
    },
    {
      "QualifierName": [
        "adverse effects"
      ],
      "DescriptorName": "Selective Serotonin Reuptake Inhibitors"
    }
  ],
  "CoiStatement": "Conflicts of Interest and Source of Funding: The author has no conflicts of interest to declare."
}